

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/06/30	2017/12/31	2017/06/30
Balance Sheet			
Current assets			
Cash and cash equivalents	359,385	342,061	445,681
Current financial assets at amortised cost	114,917	0	0
Current investments in debt instrument without active market	0	283,586	215,553
Accounts receivable, net	25,554	67,304	31,236
Accounts receivable due from related parties, net	4,089	1,533	14,037
Other receivables	6,625	1,262	3,527
Current tax assets	571	2,225	2,064
Current inventories	53,368	46,206	59,368
Prepayments	20,533	11,586	23,356
Other current assets	1,071	9,928	5,718
Total current assets	586,113	765,691	800,540
Non-current assets			
Non-current financial assets at fair value through other comprehensive income	110,221	0	0
Non-current financial assets at cost	0	87,000	87,000
Property, plant and equipment	365,432	363,827	359,285
Intangible assets	13,773	1,957	2,225
Deferred tax assets	63,256	56,696	38,820
Other non-current assets	43,028	37,628	25,267
Total non-current assets	595,710	547,108	512,597
Total assets	1,181,823	1,312,799	1,313,137
Current liabilities			
Current contract liabilities	5,257	0	0
Accounts payable	14,744	9,567	23,587
Accounts payable to related parties	263	0	0
Other payables	72,312	114,951	41,405
Other payables to related parties	0	321	0
Other current liabilities	331	2,941	13,891
Total current liabilities	92,907	127,780	78,883
Non-current liabilities			
Other non-current liabilities	41,124	41,153	2,241
Total non-current liabilities	41,124	41,153	2,241
Total liabilities	134,031	168,933	81,124
Share capital			
Ordinary share	1,121,545	1,121,180	1,120,885
Advance receipts for share capital	0	604	599
Total share capital	1,121,545	1,121,784	1,121,484
Capital surplus			
Capital surplus, additional paid-in capital	266,733	266,494	265,798
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	36,339	29,856	25,180
Total capital surplus	305,884	299,162	293,790
Retained earnings			
Unappropriated retained earnings (accumulated deficit)	-315,247	-189,469	-95,650
Total retained earnings	-315,247	-189,469	-95,650
Other equity interest			
Total other equity interest	23,221	0	0
Treasury shares	-87,611	-87,611	-87,611
Equity attributable to former owner of business combination under common control	0	0	0
Equity attributable to non-controlling interest before business combination under common control	0	0	0
Total equity	1,047,792	1,143,866	1,232,013
Total liabilities and equity	1,181,823	1,312,799	1,313,137
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	0	36,500	29,500
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/2nd	2017/2nd	2018/01/01To2018/06/30	2017/01/01To2017/06/30
Income Statement				
Total operating revenue	48,440	74,024	65,887	99,258
Total operating costs	43,792	44,195	84,538	84,828
Gross profit (loss) from operations	4,648	29,829	-18,651	14,430
Gross profit (loss) from operations	4,648	29,829	-18,651	14,430
Operating expenses				
Selling expenses	3,482	5,105	5,837	7,052
Administrative expenses	9,675	10,495	18,522	21,518
Research and development expenses	70,436	44,936	105,284	85,042
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	-244	0	631	0
Total operating expenses	83,349	60,536	130,274	113,612
Net operating income (loss)	-78,701	-30,707	-148,925	-99,182
Non-operating income and expenses				
Total other income	8,295	7,539	9,294	13,829
Other gains and losses, net	15,026	482	7,441	-9,991
Finance costs, net	74	0	148	0
Total non-operating income and expenses	23,247	8,021	16,587	3,838
Profit (loss) from continuing operations before tax	-55,454	-22,686	-132,338	-95,344
Total tax expense (income)	120	207	-6,514	306
Profit (loss) from continuing operations	-55,574	-22,893	-125,824	-95,650
Profit (loss)	-55,574	-22,893	-125,824	-95,650
Other comprehensive income				
Components of other comprehensive income that will not be reclassified to profit or loss				
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	-5,569	0	-5,569	0
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	0	0	-46	0
Total other comprehensive income	-5,569	0	-5,523	0
Total comprehensive income	-61,143	-22,893	-131,347	-95,650
Basic earnings per share				
Total basic earnings per share	-0.51	-0.21	-1.14	-0.87

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/01/01To2018/06/30	2017/01/01To2017/06/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-132,338	-95,344
Profit (loss) before tax	-132,338	-95,344
Depreciation expense	36,454	28,377
Amortization expense	784	488
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	631	68
Interest expense	148	0
Interest income	-2,781	-2,607
Share-based payments	6,483	10,106
Loss (gain) on disposal of property, plan and equipment	8	-99
Impairment loss on non-financial assets	1,989	431
Total adjustments to reconcile profit (loss)	43,716	36,764
Decrease (increase) in accounts receivable	41,119	-7,976
Decrease (increase) in accounts receivable due from related parties	-2,556	10,435
Decrease (increase) in other receivable	-5,619	-847
Decrease (increase) in inventories	-9,151	-9,404
Decrease (increase) in prepayments	-8,947	-3,367
Decrease (increase) in other current assets	-251	108
Total changes in operating assets	14,595	-11,051
Increase (decrease) in contract liabilities	3,374	0
Increase (decrease) in accounts payable	5,177	1,518
Increase (decrease) in accounts payable to related parties	263	0
Increase (decrease) in other payable	-51,168	-5,117
Increase (decrease) in other payable to related parties	-321	-6
Increase (decrease) in other current liabilities	-727	8,163
Increase (decrease) in net defined benefit liability	-29	-30
Total changes in operating liabilities	-43,431	4,528
Total changes in operating assets and liabilities	-28,836	-6,523
Total adjustments	14,880	30,241
Cash inflow (outflow) generated from operations	-117,458	-65,103
Income taxes refund (paid)	1,654	-157
Net cash flows from (used in) operating activities	-115,804	-65,260
Cash flows from (used in) investing activities		
Proceeds from disposal of available-for-sale financial assets	-49,500	0
Proceeds from capital reduction of available-for-sale financial assets	218,169	0
Acquisition of investments in debt instrument without active market	0	-83,089
Proceeds from disposal of investments in debt instrument without active market	0	352,935
Acquisition of financial assets at cost	0	-67,000
Acquisition of property, plant and equipment	-265	-24,330
Proceeds from disposal of property, plant and equipment	124	114
Increase in refundable deposits	70	-450
Acquisition of intangible assets	-1,820	-371
Increase in other financial assets	-3,493	-5,107
Decrease in other financial assets	12,601	47,683
Increase in prepayments for business facilities	-45,526	-16,014
Increase in other prepayments	-269	-7,380
Interest received	3,037	2,765
Net cash flows from (used in) investing activities	133,128	199,756
Cash flows from (used in) financing activities		
Exercise of employee share options	0	1,414
Net cash flows from (used in) financing activities	0	1,414
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	17,324	135,910
Cash and cash equivalents at beginning of period	342,061	309,771
Cash and cash equivalents at end of period	359,385	445,681
Cash and cash equivalents reported in the statement of financial position	359,385	445,681
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

2018/06/30 Statement of Stockholders' Equity

Unit: NTS thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets (or disposal groups) classified as held for sale	Other	Total other equity interest	Treasury shares	Total equity	
Equity at beginning of period	1,121,180	604	1,121,784	299,162	-189,469	-189,469	0	0	0	0	0	0	28,790	0	-87,611	1,143,860
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	0	0	0	0	0	0	28,790	0	0	28,790
Equity at beginning of period after adjustments	1,121,180	604	1,121,784	299,162	-189,469	-189,469	0	0	0	0	0	0	28,790	0	-87,611	1,172,650
Profit (loss)	0	0	0	0	-125,824	-125,824	0	0	0	0	0	0	0	0	0	-125,824
Other comprehensive income	0	0	0	0	46	46	0	0	0	0	0	0	0	0	0	-5,529
Total comprehensive income	0	0	0	0	-125,778	-125,778	0	0	0	0	0	0	0	0	0	-11,147
Share-based payments	365	-604	-239	6,722	0	0	0	0	0	0	0	0	0	0	0	6,483
Total increase (decrease) in equity	365	-604	-239	6,722	-125,778	-125,778	0	0	0	0	0	0	0	0	0	-124,864
Equity at end of period	1,121,545	0	1,121,545	305,884	-315,247	-315,247	0	0	0	0	0	0	23,221	0	-87,611	1,047,732

2017/06/30 Statement of Stockholders' Equity

Unit: NTS thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) on financial assets measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets (or disposal groups) classified as held for sale	Other	Total other equity interest	Treasury shares	Total equity		
Equity at beginning of period	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	0	-87,611	1,316,143	
Equity at beginning of period after adjustments	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	0	0	-87,611	1,316,143
Capital surplus used to offset accumulated deficits	0	0	0	-356,669	356,669	0	0	0	0	0	0	0	0	0	0	0	0	
Profit (loss)	0	0	0	0	-95,650	-95,650	0	0	0	0	0	0	0	0	0	0	-95,650	
Total comprehensive income	0	0	0	0	-95,650	-95,650	0	0	0	0	0	0	0	0	0	0	-95,650	
Share-based payments	880	-208	672	10,848	0	0	0	0	0	0	0	0	0	0	0	0	11,520	
Total increase (decrease) in equity	880	-208	672	10,848	-95,650	-84,802	0	0	0	0	0	0	0	0	0	0	-84,130	
Equity at end of period	1,120,885	599	1,121,484	293,790	-452,270	-452,270	0	0	0	0	0	0	0	0	0	0	-87,611	1,232,013